The central role of the CD40-ligand and CD40 pathway in T-lymphocyte-mediated differentiation of B lymphocytes

Current Opinion in Hematology

Volumn 3, Issue 1, 1996, Pages 77-86

  Lederman, Seth ^a   Cleary, Aileen M ^a   Yellin, Michael J ^a   Frank, Dale M ^a   Karpusas, Michael ^b   Thomas, David W ^b   Chess, Leonard ^a  

^a Columbia University ^*  (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

B LYMPHOCYTE DIFFERENTIATION; EPSTEIN BARR VIRUS; HELPER CELL; HUMAN; LYMPHOCYTE CLONE; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS CELL TRANSFORMATION;

EID: 0029995547     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603010-00012     Document Type: Review

References (118)

1. Lederman S, Yellin MJ, Krinchevsky A, Belko J, Lee JJ, Chess L: Identification of a novel surface protein on activated CD4+ T cells that induces contact dependent B cell differentiation (help). J Exp Med 1992, 175:1091-1101.
2. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, MacDuff BM, Anderson DM, Gimpel SD, Davis Smith T, Maliszewski CR: Molecular and biological characterization of a murine ligand for CD40. Nature 1992, 357:80-82.
3. Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L: Molecular interactions mediating T-B lymphocyte collaboration in human lymphold follicles: roles of T-B activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol 1992, 149:3817-3826.
4. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A: A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A 1992, 89:6550-6554.
5. Graf D, Korthauer U, Mages HW, Senger G, Kroczek RA: Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 1992, 22:3191-3194.
6. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch Andersen S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992, 11:4313-4321.
7. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, MacDuff BM, Sato TA, Maliszewski CR, Fanslow WC: Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992, 176:1543-1550.
8. Lane P, Traunecker A, Hubele S, Inui S, Lanzavecchia A, Gray D: Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol 1992, 22:2573-2578.
9. Hermann P, Blanchard D, De Saint Vis B, Fossiez F, Gaillard C, Vanbervliet B, Briere F, Banchereau J, Galizzi JP: Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes. Eur J Immunol 1993, 23:961-964.
10. Gauchat JF, Aubry JP, Mazzei G, Life P, Jomotte T, Elson G, Bonnefoy JY: Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett 1993, 315:259-266.
11. Covey LR, Cleary AM, Yellin MJ, Ware R, Sullivan G, Belko J, Parker M, Rothman P, Chess L, Lederman S: Isolation of a cDNA encoding T-BAM, a surface glycoprotein on CD4+ T cells mediating contact-dependent helper function for B cells: identity with the CD40-Ligand. Mol Immunol 1994, 31:471-484.
12. Crow MK, Jover JA, Friedman SM: Direct T helper-B cell interactions induce an early B cell activation antigen. J Exp Med 1986, 164:1760-1772.
13. Noelle RJ, Snow EC: Cognate interactions between helper T cells and B cells. Immunol Today 1990, 11:361-368.
14. Yellin MJ, Lee JJ, Chess L, Lederman S: A human CD4-leukemic subclone with contact dependent helper function. J Immunol 1991, 147:3389-3395.
15. Lederman S, Yellin MJ, Covey LR, Cleary AM, Callard R, Chess L: Non-antigen signals for B-cell growth and differentiation to antibody secretion. Curr Opin Immunol 1993, 5:439-444.
16. Phillips JM, Waldmann H: Monogamous T helper cell. Nature 1977, 268:641-642.
17. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, DeFrance T: Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992, 80:3173-3181.
18. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993, 177:925-935.
19. Yellin MJ, Sinning J, Covey LR, Sherman W, Lee JJ, Glickman-Nir E, Sippel KC, Rogers J, Cleary AM, Parker M, Chess L, Lederman S: T lymphocyte T cell-B cell activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994, 153:666-674.
20. Klaus SJ, Pinchuk LM, Ochs HD, Law CL, Fanslow WC, Armitage RJ, Clark EA: Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. J Immunol 1994, 152:5643-5652.
21. Clark EA, Ledbetter JA: How B and T cells talk to each other. Nature 1994, 367:425-428.
22. Cayabyab M, Phillips JH, Lanier LL: CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol 1994, 152:1523-1531.
23. Grabstein KH, Maliszewski CR, Shanebeck K, Sato TA, Spriggs MK, Fanslow WC, Armitage RJ: The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2. J Immunol 1993, 150:3141-3147.
24. Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE, Covey LR, Lee JJ, Rothman P, Chess L: The T-BAM/CD40-L molecule on helper T lymphocytes augments lymphokine-induced B cell immunoglobulin isotype switch recombination and rescues B cells from programmed cell death. J Immunol 1994, 152:2163-2171.
25. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F: Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993, 177:1209-1213.
26. van Den Eertwegh AJM, Noelle RJ, Roy M, Shepard DM, Aruffo A, Ledbetter JA, Boersma WJA, Claassen E: In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 1993, 178:1555-1565.
27. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ: In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 1993, 178:1567-1575.
28. Rosen FS, Kevy SV, Merler E: Recurrent bacterial infections and dysgammaglobulinemia: deficiency of 7S gammaglobulin in the presence of elevated 19S gammaglobulins. Pediatrics 1961, 28:182-195.
29. Mayer L, Kwan SP, Thompson C, Ko HS, Chiorazzi N, Waldmann T, Rosen F: Evidence for a defect in "switch" T cells in patients with immunodeficiency and hyperimmunoglobulinemia M. N Engl J Med 1986, 314:409-413.
30. Notarangelo LD, Duse M, Ugazio AG: Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 1992, 3:101-121.
31. Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen RS, Chatila T, Fu SM, Stamenkovic I, Geha RS: Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A 1993, 90:2170-2173.
32. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA: Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993, 361:539-541.
33. Disante JP, Bonnefoy JY, Gauchat JF, Fischer A, De Saint Basile G: CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993, 361:541-543.
34. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, Fanslow WC, Belmont J, Spriggs MK: CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993, 259:990-993.
35. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M, Roberts RL, Noelle RJ, Ledbetter JA, Francke U, Ochs HD: The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993, 72:291-300.
36. Ramesh N, Fuleihan R, Ramesh V, Lederman S, Yellin MJ, Sharma S, Chess L, Rosen FS, Geha RS: Novel deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Int Immunol 1993, 5:769-774.
37. Durandy A, Schiff C, Bonnefoy JY, Forveille M, Rousset F, Mazzei G, Milili M, Fischer A: Induction by anti-CD40 antibody or soluble CD40 ligand and cytokines of IgG, IgA and IgE production by B cells from patients with X-linked hyper IgM syndrome. Eur J Immunol 1993, 23:2294-2299.
38. Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA: Mice deficient for the CD40 ligand. Immunity 1994, 1:423-431.
39. Renshaw BR, Fanslow WC, 3RD, Armitage RJ, Campbell KA, Liggitt D, Wright B, Davison BL, Maliszewski CR: Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994, 180:1889-1900.
40. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yosida N, Kishimoto T, Kikytani H: The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1994, 1:167-178.
41. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ: The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993, 151:2497-2510.
42. Cronin DC II, Stack R, Fitch FW: IL-4-producong CD8+ T cell clones can provide B cell help. J Immunol 1995, 154:3118-3127.
43. Casamayor-Palleja C, Khan M, MacLennan ICM: A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J Exp Med 1995, 181:1293-1301.
44. Mohan C, Shi Y, Laman JD, Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995, 154:1470-1480.
45. Yellin MJ, Sippel KC, Inghirami G, Covey LR, Lee JJ, Sinning J, Clark EA, Chess L, Lederman S: CD40 molecules induce down-modulation and endocytosis of T cell surface T-BAM/CD40-L: potential role in regulating helper effector function. J Immunol 1994, 152:598-608. Describes how CD40-L is rapidly downregulated by interactions with CD40 on other cells, which results in degradation of CD40-L in cytoplasmic vesicles and may be important in maintaining T- and B-cell monogamy.
46. van Kooten C, Gaillard C, Galizzi J-P, Hermann P, Fossiez F, Banchereau J, Blanchard D: B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through release of soluble CD40. Eur J Immunol 1994, 24:787-792.
47. Liu Y, Johnson GD, Gordon J, MacLennan ICM: Germinal centers in T-cell-dependent antibody responses. Immunol Today 1992, 13:17-21.
48. Facchetti F, Appiani C, Salvi L, Levy J, Notarangelo LD: Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-llnked immunodeficiency with hyper-IgM. J Immunol 1995, 154:6624-6633. A detailed immunohistologic study of X-linked hyper-Igm syndrome using monoclonal antibodies that characterize the abnormalities in dendritic cells in human CD40-L deficiency.
49. Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G: Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol 1995, 155:556-567. Treatment of mice with anti-CD40-L results in dissolution of existing germinal centers and emphasizes the importance of CD40-L and CD40 interactions for the maintenance of germinal centers.
50. Jumper MD, Splawski JB, Lipsky PE, Meek K: Ligation of CD40 induces sterile transcripts of multiple IgH chain isotypes in human B cells. J Immunol 1994, 152:438-445.
51. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC: Mechanism of antigen-driven selection in germinal centres. Nature 1989, 342:929-931.
52. Liu YJ, Mason DY, Johnson GD, Abbot S, Gregory CD, Hardie DL, Gordon J, MacLennan IC: Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosls. Eur J Immunol 1991, 21:1905-1910.
53. Valentine MA, Licciardi KA: Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40. Eur J Immunol 1992, 22:3141-3148.
54. Tsubata T, Wu J, Honjo T: B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993, 364:645-648.
55. Holder MJ, Wang H, Milner AE, Casamayor M, Armitage R, Spriggs MK, Fanslow WC, MacLennan IC, Gregory CD, Gordon J, et al.: Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur J Immunol 1993, 23:2368-2371.
56. Pulendran B, Kannourakis G, Nouri S, Smith KG, Nossal GJ: Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. Nature 1995, 375:331-334.
57. Shokat KM, Goodnow CC: Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature 1995, 375:334-338.
58. Parry SL, Hasbold J, Holman M, Klaus GGB: Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40. J Immunol 1994, 152:2821-2829.
59. Rudich SM, Roux KH, Winchester RJ, Mongini PK: Anti-IgM-mediated B cell signaling. Molecular analysis of ligand binding requisites for human B cell clonal expansion and tolerance. J Exp Med 1988, 168:247-266.
60. Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S: Roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human B cells. J Immunol 1995, 155:3329-3337. This study shows the opposing effects of CD40 and Fas in mediating the positive and negative selection of human germinal center B cells. It provides the experimental basis for a new model of how germinal centers function.
61. Moller P, Henne C, Leithauser F, Eichelmann A, Schmidt A, Bruderlein S, Dhein J, Krammer PH: Deregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 1993, 81:2067-2075.
62. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305.
63. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
64. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
65. Daniel PT, Krammer PH: Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994, 152:5624-5632.
66. Rothstein TL, Wang JKM, Panka DJ, Foote LC, Wang Z, Stanger B, Cul H, Ju S, Marshak-Rothstein A: Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995, 374:163-165.
67. Watanabe Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
68. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349. This study of humans with Fas mutations demonstrates the importance of Fas in limiting autoimmunity. See also the study by Fisher et al. (Cell 1995, 81:935-946).
69. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349. This study of humans with Fas mutations demonstrates the importance of Fas in limiting autoimmunity. See also the study by Fisher et al. (Cell 1995, 81:935-946).
70. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946. This study establishes the role of Fas in limiting autoimmunity. See also Rieux-Laucat (Science 1995, 268:1347-1349).
71. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946. This study establishes the role of Fas in limiting autoimmunity. See also Rieux-Laucat (Science 1995, 268:1347-1349).
72. Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994, 179:873-879.
73. Matzinger P: Tolerance, danger and the extended family. Annu Rev Immunol 1994, 12:991-1045.
74. Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ: Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor. J Immunol 1993, 151:7273-7283.
75. Arpin C, Dechanet J, van Kooten C, Merville P, Grouard G, Briere F, Banchereau J, Liu Y: Generation of memory B cells and plasma cells in vitro. Science 1995, 268:720-722. This study clearly demonstrates the manner in which the state of B-cell differentiation modulates the CD40 responsiveness in B cells.
76. Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ: gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994, 180:157-163.
77. Berberich I, Shu GL, Clark EA: Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 1994, 153:4357-4366.
78. Choi MSK, Brines RD, Holman MJ, Klaus GGB: Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. Immunity 1995, 1:179-187.
79. Choi MS, Boise LH, Gottschalk AR, Quintans J, Thompson CB, Klaus GG: The role of bcl-XL in CD40-mediated rescue from anti-mu-induced apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 1995, 25:1352-1357. Whereas the CD40-induced upregulation of bcl-2 is relatively modest, this study shows that CD40 induction of bcl-xL may be critical in the program of rescue from apoptosis.
80. Sarma V, Lin Z, Clark L, Rust BM, Tewari M, Noelle RJ, Dixit VM: Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosls. J Biol Chem 1995, 270:12343-12346. These data clearly suggest that A20 plays a role in protecting B cells from apoptosis.
81. Ren CL, Fu SM, Geha RS: Protein tyrosine kinase activation and protein kinase C translocation are functional components of CD40 signal transduction in resting human B cells. Immunol Invest 1994, 23:437-448.
82. Hasbold J, Klaus GGB: B cells from CBA/N mice do not proliferate following ligation of CD40. Eur J Immunol 1995, 24:152-157.
83. Ren CL, Morio T, Fu SM, Geha RS: Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med 1994, 179:673-680.
84. Worm M, Geha RS: Activation of tumor necrosis factor-alpha and lymphotoxin-alpha via anti-CD40 in human B cells. Int Arch Allergy Immunol 1995, 107:368-369.
85. Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE: Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A 1994, 91:7007-7011.
86. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers [review]. FASEB J 1995, 9:899-909.
87. Koopman G, Keehnen RMJ, Lindhout E, Newman W, Shimizu Y, van Seventer GA, de Groot C, Pals ST: Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994, 152:3760-3767.
88. Inui S, Kaisho T, Kikutani H, Stamenkovic I, Seed B, Clark EA, Kishimoto T: Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40. Eur J Immunol 1990, 20:1747-1753.
89. Cheng G, Cleary AM, Ye Z, Hong DI, Lederman S, Baltimore D: Involvement of CRAF-1, a relative of TRAF, in CD40 signaling. Science 1995, 267:1494-1497. In addition to identifying CRAF-1 on the basis of binding to the cytoplasmic tail of CD40, this study demonstrates a role for CRAF-1 in CD40 signaling and is the first evidence demonstrating a functional role for a TRAF family member.
90. Hu HM, O'Rourke K, Boguski MS, Dixit VM: A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 1994, 269:30069-30072. One of the studies that identified CRAF-1 (CD40bp) using the yeast two-hybrid system and showed a negative correlation of binding to CD40 tail with mutations that were known to disrupt CD40 function.
91. Mosialos G, Birkenbach M, Yalamanchili R, Vanarsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995, 80:389-399. This study identified CRAF-1 (LAP1) by yeast two-hybrid binding with LMP-1 of Epstein-Barr virus. It also showed the binding of CRAF-1 with fusion proteins containing the cytoplasmic tails of CD40 and lymphotoxin β receptor.
92. Sato T, Irie S, Reed JC: A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett 1995, 358:113-118.
93. Rothe M, Wong SC, Henzel WJ, Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78:681-692. Identified the first two members of the TRAF family.
94. Crowe PD, Vanarsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA: A lymphotoxin-beta-specific receptor. Science 1994, 264:707-710.
95. Browning JL, Ngam EK A, Lawton P, DeMarinis J, Tizard R, Chow EP, Hession C, Obrine Greco B, Foley SF, Ware CF: Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993, 72:847-856.
96. Rothe M, Sarma V, Dixit VM, Goeddel DV: TRAF1-mediated activation of NF-kappa-B by TNF receptor 2 and CD40. Science 1995, 269:1424-1427.
97. Lehel C, Olah Z, Jakab G, Anderson WB: Protein kinase C epsilon is localized to the Golgi via its zinc-finger domain and modulates Golgi function. Proc Natl Acad Sci U S A 1995, 92:1406-1410.
98. Banner DW, D'arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73:431-445. Cocrystallization of lymphotoxin α and TNFαaRI and solution of their structures is tho paradigm for understanding interactions between ligand and receptor in the TNFα and TNFα receptor families.
99. Peitsch MC, Jongeneel CV: A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol 1993, 5:233-238.
100. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR: Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 1995, 270:13303-13307. This intriguing study suggests that the structures of TNFα receptor forms are modulated by ligand.
101. Stamenkovic I, Clark EA, Seed B: A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989, 8:1403-1410.
102. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994, 76:959-962.
103. Karpusas M, Hsu Y-M, Wang J-H, Thompson J, Lederman S, Chess L, Thomas D: Two angstrom crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995, 3:1031-1039. The crystal structure of CD40-L demonstrates its trimeric nature and provides atomic detail in imagining how CD40-L interacts with CD40.
104. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY: Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995, 270:7025-7028.
105. Braesch Andersen S, Paulie S, Koho H, Nika H, Aspenstrom P, Perlmann P: Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen CDw40. J Immunol 1989, 142:562-567.
106. Armitage RJ, Sato TA, MacDuff BM, Clifford KN, Alpert AR, Smith CA, Fanslow WC: Identification of a source of biologically active CD40 ligand. Eur J Immunol 1992, 22:2071-2076.
107. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995, 25:1749-1754.
108. Mercep M, Weissman AM, Frank SJ, Klausner RD, Ashwell JD: Activation-driven programmed cell death and T cell receptor zeta eta expression. Science 1989, 246:1162-1165.
109. Fuleihan R, Ramesh N, Horner A, Ahern D, Belshaw PJ, Alberg DG, Stamenkovic I, Harmon W, Geha RS: Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J Clin Invest 1994, 93:1315-1320.
110. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF: CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 1994, 152:117-128.
111. Tong AW, Zhang B-Q, Mues G, Solano M, Hanson T, Stone MJ: Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood 1995, 84:3026-3033.
112. Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, Lundgren E, Rickinson AB: Upregulatlon of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994, 68:5602-5612.
113. Gregory CD, Rowe M, Rickinson AB: Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 1995, 71:14810-1495.
114. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E: Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990, 64:2309-2318.
115. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991, 65:1107-1115.
116. Zhang Q, Brooks L, Busson P, Wang F, Charron D, Kieff E, Rickinson AB, Tursz T: Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line. Eur J Immunol 1994, 24:1467-1470.
117. Martin JM, Veis D, Korsmeyer SJ, Sugden B: Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol 1993, 67:5269-5278.
118. Chiorazzi N, Fu SM, Montazeri G, Kunkel HG, Rai K, Gee T: T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol 1979, 122:1087-1090.